A detailed history of Northern Trust Corp transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 577,267 shares of VERV stock, worth $2.63 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
577,267
Previous 572,223 0.88%
Holding current value
$2.63 Million
Previous $2.79 Million 0.04%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$4.4 - $7.86 $22,193 - $39,645
5,044 Added 0.88%
577,267 $2.79 Million
Q2 2024

Aug 14, 2024

SELL
$4.76 - $12.79 $40,740 - $109,469
-8,559 Reduced 1.47%
572,223 $2.79 Million
Q1 2024

May 14, 2024

BUY
$10.81 - $17.96 $945,788 - $1.57 Million
87,492 Added 17.74%
580,782 $7.71 Million
Q4 2023

Feb 13, 2024

BUY
$8.84 - $18.7 $238,397 - $504,301
26,968 Added 5.78%
493,290 $6.88 Million
Q3 2023

Nov 13, 2023

BUY
$11.42 - $20.82 $92,319 - $168,308
8,084 Added 1.76%
466,322 $6.18 Million
Q2 2023

Aug 11, 2023

BUY
$13.34 - $19.9 $729,364 - $1.09 Million
54,675 Added 13.55%
458,238 $8.59 Million
Q1 2023

May 15, 2023

BUY
$14.3 - $24.01 $52,910 - $88,837
3,700 Added 0.93%
403,563 $5.82 Million
Q4 2022

Feb 13, 2023

BUY
$17.85 - $40.7 $195,403 - $445,542
10,947 Added 2.81%
399,863 $7.74 Million
Q3 2022

Nov 14, 2022

BUY
$15.63 - $41.49 $1.69 Million - $4.48 Million
108,001 Added 38.45%
388,916 $13.4 Million
Q2 2022

Aug 12, 2022

BUY
$11.14 - $23.17 $15,774 - $32,808
1,416 Added 0.51%
280,915 $4.29 Million
Q1 2022

May 13, 2022

BUY
$20.92 - $39.36 $2.82 Million - $5.31 Million
134,914 Added 93.31%
279,499 $6.38 Million
Q4 2021

Feb 08, 2022

BUY
$31.94 - $54.82 $143,538 - $246,361
4,494 Added 3.21%
144,585 $5.33 Million
Q3 2021

Nov 15, 2021

BUY
$46.0 - $73.99 $6.44 Million - $10.4 Million
140,091 New
140,091 $6.58 Million

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $273M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.